Bicara Therapeutics (BCAX) Current Leases (2023 - 2026)

Bicara Therapeutics' Current Leases history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Current Leases rose 92.89% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 92.89% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 84.02% from the prior year.
• Current Leases advanced to $1.1 million in Q1 2026 per BCAX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Current Leases topped out at $1.1 million in Q1 2026 and bottomed at $285000.0 in Q4 2023.
• The 4-year median for Current Leases is $840500.0 (2024), against an average of $777125.0.
• Biggest YoY gain for Current Leases was 255.52% in 2025; the steepest drop was 84.02% in 2025.
• Year by year, Current Leases stood at $285000.0 in 2023, then surged by 112.98% to $607000.0 in 2024, then surged by 84.02% to $1.1 million in 2025, then rose by 2.06% to $1.1 million in 2026.
• Per Business Quant, the three latest BCAX Current Leases figures stand at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).